Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Condition: Bladder Cancer; Muscle-invasive Bladder Cancer
MeSH terms: Urinary Bladder Neoplasms; Carcinoma, Transitional Cell
Intervention: Methotrexate; Doxorubicin; vinblastine; cisplatin; Pegfilgrastim
Intervention description: intravenously 30mg/m2 over 30 minutes; intravenously 30mg/ms over 15 minutes; intravenously 3mg/m2 over 30 minutes; intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion; Given subcutaneously 24 hours after last chemotherapy dose
Intervention MeSH terms: Doxorubicin; Methotrexate; Vinblastine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 39.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: pegfilgrastim; MVAC

Summary:

      The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense
      methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with
      pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial
      carcinoma.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologic proof of urothelial cancer. Patients with all histologic subtypes are
             eligible as long as transitional cell carcinoma is predominant, with the exception of
             more than a few clusters of small cell carcinoma, which is treated with different
             chemotherapy and thus are ineligible

          -  Patients with primary tumors arising in the bladder or urethra are eligible if they
             have clinical T2-T4a disease

          -  Patients with primary tumors arising in the ureter or renal pelvis are eligible if
             they have either grade 3 tumors, or radiographic abnormality large enough to be
             recognized as an abnormal mass by CT/imaging

          -  Evaluation by a urologist and be deemed to be acceptable surgical candidates within 3
             months of registration

          -  Adequate physiologic reserves as outlined in the protocol

          -  Clinical or pathologic N1 lymph node involvement (involvement of a single lymph node <
             2cm in greatest dimension) are eligible. Patients with N2-3 or M1 disease are
             ineligible

          -  Determination of LV function with an EF > 50%

          -  Women of child-bearing potential must have a negative pregnancy test

          -  Patients of child-bearing or father-bearing potential must agree to use an acceptable
             form of birth control while on the study

          -  Patients with prior malignancy are eligible provided that the expected outcome from
             the prior cancer is such that this will not interfere in the delivery of this therapy,
             or the assessment of response in the cystectomy specimen

          -  18 years of age or older

        Exclusion Criteria:

          -  Current, recent (within 3 weeks), or planned participation with other experimental
             anti-cancer medications as part of clinical trials

          -  Prior treatment with doxorubicin

          -  Prior systemic cytoreductive chemotherapy for bladder cancer

          -  Blood pressure of > 160/100 mmHg. Patients whose blood pressure can be controlled with
             oral medication are eligible

          -  NYHA Grade II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 6 months prior to study
             enrollment

          -  History of stroke or transient ischemic attack within 6 months prior to study
             enrollment

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Known history of central nervous system or brain metastases

          -  Major surgical procedure, significant traumatic injury within 21 days prior to Day 1,
             or anticipation of need for major surgical procedure during the course of the study

          -  Lactating women

          -  Patients who are not candidates for surgery, or unwilling to undergo surgery

          -  Patients with significant fluid collection

          -  Known hypersensitivity to any component of cisplatin, methotrexate, vinblastine,
             doxorubicin or pegfilgrastim